Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 15/20 | 0.72 |
| ▸ | TACR2 | P21452 | 7/20 | 0.72 |
| ▸ | TACR3 | P29371 | 7/20 | 0.72 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.59 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5733490 | 0.99 | TRPV4 (0.71) | TRPV4TACR2TACR3OPRM1KCNH2 | |
| SCHEMBL5443753 | 0.93 | TRPV4 (0.64) | TRPV4TACR2TACR3OPRM1KCNH2 | |
| SCHEMBL6428018 | 0.92 | TRPV4 (0.70) | TRPV4TACR2TACR3OPRM1KCNH2 | |
| SCHEMBL6855974 | 0.92 | TACR3 (0.70) | TRPV4TACR2TACR3OPRM1KCNH2 | |
| SCHEMBL5733751 | 0.91 | TACR3 (0.62) | TRPV4TACR2TACR3OPRM1KCNH2 | |
| SCHEMBL5447103 | 0.91 | TRPV4 (0.75) | TRPV4TACR2TACR3OPRM1KCNH2 | |
| SCHEMBL5945353 | 0.90 | TRPV4 (0.63) | TRPV4TACR2TACR3OPRM1KCNH2 | |
| SCHEMBL5203642 | 0.90 | TRPV4 (0.73) | TRPV4TACR2TACR3OPRM1KCNH2 | |
| Hydrochloric Acid SCHEMBL2372819 | 0.90 | TRPV4 (0.74) | TRPV4TACR2TACR3OPRM1KCNH2 | |
| SCHEMBL5945439 | 0.90 | TRPV4 (0.60) | TRPV4TACR2TACR3OPRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6780875-B2 | RESPIRATORY SYSTEM DISORDERS; ANTIINFLAMMATORY AGENTS; PSYCHOLOGICAL DISORDERS | SMITHKLINE BEECHAM S.P.A. (IT) | 2004-08-24 | — | — | US | claimed |
| WO-2011119704-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
| EP-1377555-B1 | A DIOXINO[2,3-G]QUINOLINE-9-CARBOXYLIC ACID DERIVATIVE AS NK3 RECEPTOR ANTAGONIST | GLAXOSMITHKLINE SPA (IT) | 2007-01-24 | — | — | EP | disclosed |
| EP-1131294-B1 | QUINOLINE DERIVATIVES AS NK-2 AND NK-3 RECEPTOR LIGANDS | GLAXOSMITHKLINE SPA (IT) | 2006-12-20 | — | — | EP | disclosed |
| US-20060161004-A1 | Novel compounds | GLAXOSMITHKLINE SPA | 2006-07-20 | — | — | US | disclosed |
| US-20050182093-A1 | Novel compounds | GLAXOSMITHKLINE S.P.A. | 2005-08-18 | — | — | US | disclosed |
| US-20050070574-A1 | Novel compounds | GLAXOSMITHKLINE SPA AND LABORATOIRE | 2005-03-31 | — | — | US | disclosed |
| US-6855723-B2 | Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds | ZENTARIS GMBH (DE) | 2005-02-15 | — | — | US | disclosed |
| US-6780875-B2 | RESPIRATORY SYSTEM DISORDERS; ANTIINFLAMMATORY AGENTS; PSYCHOLOGICAL DISORDERS | SMITHKLINE BEECHAM S.P.A. (IT) | 2004-08-24 | — | — | US | disclosed |
| US-20040152730-A1 | Novel compounds | SMITHKLINE BEECHAM S.P.A. (IT) | 2004-08-05 | — | — | US | disclosed |
| US-20040102633-A1 | Novel compounds | GLAXOSMITHKLINE S.P.A. (IT) | 2004-05-27 | — | — | US | disclosed |
| EP-1377555-A1 | NOVEL COMPOUNDS | GlaxoSmithKline S.p.A. (IT) | 2004-01-07 | — | — | EP | disclosed |
| US-20030212101-A1 | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | SMITHKLINE BEECHAM S.P.A. (IT) | 2003-11-13 | — | — | US | disclosed |
| EP-1339691-A1 | NOVEL COMPOUNDS | GlaxoSmithKline S.p.A. (IT) | 2003-09-03 | — | — | EP | disclosed |
| US-6613770-B1 | Neurokinin antagonists such as 3-(4-Isopropyl-piperazin-yl-methyl)-2-phenyl-quinoline-4-carboxylic acid (1,2-dimethyl-propyl)-amide dihydrochloride, used for prophylaxis of respiratory and gastrointerstinal disorders | SMITHKLINE BEECHAM S.P.A. (IT) | 2003-09-02 | — | — | US | disclosed |
| WO-2002083645-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE S.P.A. (IT) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002044154-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE SPA (IT) | 2002-06-06 | — | — | WO | disclosed |
| EP-1131294-A1 | QUINOLINE DERIVATIVES AS NK-2 AND NK-3 RECEPTOR LIGANDS | Smithkline Beecham S.p.A. (IT) | 2001-09-12 | — | — | EP | disclosed |
| WO-2000031038-A1 | QUINOLINE DERIVATIVES AS NK-2 AND NK-3 RECEPTOR LIGANDS | SMITHKLINE BEECHAM S.P.A. (IT) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070574-A1 | Novel compounds | NR1H3, NR1H2, CNR1 | TRPV4 1565/4885TACR2 52/4885TACR3 301/4885 |
| US-20050182093-A1 | Novel compounds | SLC10A1, AVPR2, REN | TRPV4 1507/4885TACR2 1103/4885TACR3 3323/4885 |
| US-20030212101-A1 | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | KCNH2, KCNA6, KCNA3 | TRPV4 1029/4885TACR2 21/4885TACR3 86/4885 |
| US-20060161004-A1 | Novel compounds | SLC10A1, ABCB11, AQP1 | TRPV4 1307/4885TACR2 862/4885TACR3 2824/4885 |
| US-20040102633-A1 | Novel compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, NR1H3 | TRPV4 2393/4885TACR2 155/4885TACR3 1027/4885 |
| US-20040152730-A1 | Novel compounds | SLC10A1, AVPR2, REN | TRPV4 1507/4885TACR2 1103/4885TACR3 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.